Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Decreases By 15.0%

ABVC BioPharma, Inc. (NASDAQ:ABVC) saw a large drop in short interest during the month of June. As of June 15th, there was short interest totalling 370,000 shares, a drop of 15.0% from the May 31st total of 435,100 shares. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is presently 0.3 days. Currently, 3.7% of the company’s shares are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in ABVC BioPharma stock. Chase Investment Counsel Corp acquired a new position in ABVC BioPharma, Inc. (NASDAQ:ABVC) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 178,377 shares of the company’s stock, valued at approximately $233,000. Chase Investment Counsel Corp owned 1.69% of ABVC BioPharma at the end of the most recent quarter. Institutional investors and hedge funds own 11.38% of the company’s stock.

ABVC BioPharma Trading Up 5.0 %

Shares of NASDAQ:ABVC opened at $0.77 on Friday. The company’s fifty day moving average is $0.98 and its 200 day moving average is $1.16. ABVC BioPharma has a 52 week low of $0.67 and a 52 week high of $6.87.

ABVC BioPharma (NASDAQ:ABVC) last announced its quarterly earnings data on Friday, May 17th. The company reported ($0.40) earnings per share (EPS) for the quarter. ABVC BioPharma had a negative net margin of 50,504.00% and a negative return on equity of 207.72%.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.